【摘要】 目的促进临床科学实施β-内酰胺类药物皮肤过敏试验(简称皮试)。方法选择408次β-内酰胺类药物皮试阳性的结果,统计皮试阳性后换用其他β-内酰胺类药物皮试的结果,计算各种β-内酰胺类药物的皮试阳性率,分析交叉皮试阳性的β-内酰胺类药物与侧链的关系。结果 83.15%的患者皮试阳性后换用其他β-内酰胺药物皮试呈阴性,皮试阳性率较高的药物是头孢曲松(1.40%)、头孢替安(1.22%)、氟氯西林(1.07%)、拉氧头孢(0.94%)。交叉皮试阳性的β-内酰胺类药物多数不具有相同或相似的侧链。结论一种β-内酰胺类药物皮试阳性后可选用另一种β-内酰胺类药物皮试,但无法从侧链相同和相似性预测皮试结果。更多还原

【Abstract】 Objective To analyze the regular pattern of beta- lactam drug anaphylactic skin test to promote the scientific implementation of the skin test of beta- lactam drugs. Methods Four hundred and eight times of the positive results of beta- lactam drug skin test were selected and changed the other beta- lactam drugs skin test,then the test results were counted and the positive rate of skin test of various beta- lactam drugs were calculated. The relation between the beta- lactam drugs with the cross positive skin tests and the side- chains was analyzed. Results 83. 15% of the patients with the positive results in one beta- lactam drug skin test had the negative skin test results when changing the other beta- lactam drugs. The beta- lactam drugs with the higher rate of positive skin test results were ceftriaxone( 1. 40%),cefotiam( 1. 22%),flucloxacillin( 1. 07%) and latamoxef( 0. 94%). Most of the beta- lactam drugs with cross skin test positive results had no same or similar side chains. Conclusion After obtaining the positive skin test result in one kind of beta- lactam drug,another beta- lactam drug can be selected to conduct the skin test,but the skin test result could not be predicted by the same side chain or similar chain.更多还原